Breaking News Instant updates and real-time market news.

ULTA

Ulta Beauty

$238.97

2.31 (0.98%)

, PGR

Progressive

$32.37

0.7 (2.21%)

09:55
10/13/16
10/13
09:55
10/13/16
09:55

Early notable gainers among liquid option names on October 13th

Notable gainers among liquid option names this morning include Ulta (ULTA) $251.16 +12.21, Progressive (PGR) $32.33 +0.64, Baxter (BAX) $47.75 +0.76, CSX (CSX) $30.63 +0.41, and Alexion (ALXN) $120.11 +1.36.

ULTA

Ulta Beauty

$238.97

2.31 (0.98%)

PGR

Progressive

$32.37

0.7 (2.21%)

BAX

Baxter

$47.51

0.53 (1.13%)

CSX

CSX

$30.21

-0.26 (-0.85%)

ALXN

Alexion

$118.75

-3.02 (-2.48%)

  • 13

    Oct

  • 13

    Oct

  • 25

    Oct

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 07

    Dec

  • 14

    Dec

ULTA Ulta Beauty
$238.97

2.31 (0.98%)

08/26/16
DBAB
08/26/16
NO CHANGE
Target $280
DBAB
Hold
Ulta Beauty price target increased to $280 from $225 at Deutsche Bank
Deutsche Bank analyst Mike Baker said Ulta Beauty reported a "terrific" quarter by "almost any measure," but noted that expectations for the retailer have become so high that in-line to slightly better result likely aren't a major positive catalyst for the stock at current levels. Baker raised his price target on Ulta shares to $280 from $225 but keeps a Hold rating on the stock.
10/11/16
BARD
10/11/16
NO CHANGE
Target $305
BARD
Outperform
Ulta Beauty risk/reward attractive ahead of investor day, says Baird
Baird analyst Mark Altschwager previewed Ulta Beauty's investor day and said the recent pullback in the shares has lead to an attractive risk/reward for investors. The analyst expects management's tone to be upbeat, for them to update progress on long term goals, and for them to clarify revenue/unit potential, margin drivers, and supply chain initiatives. Altschwager reiterated his Outperform rating and $305 price target on Ulta Beauty shares.
08/24/16
BARD
08/24/16
NO CHANGE
Target $300
BARD
Outperform
Ulta Beauty price target raised to $300 from $280 at Baird
Baird analyst Mark Altschwager raised his price target on Ulta Beauty to $300 from $280 in anticipation of solid Q2 trends, including comps and earnings that he expects to be at least in line with consensus expectations. The analyst believes the Ulta growth story remains underappreciated by the market and that its strong management justifies its premium valuation. Altschwager reiterated his Outperform rating on Ulta Beauty shares.
08/26/16
COWN
08/26/16
NO CHANGE
Target $286
COWN
Outperform
Ulta Beauty weakness a buying opportunity, says Cowen
Cowen analyst Oliver Chen said the Street's high expectations for Ulta Beauty were likely already priced into the shares, so he recommends buying the shares on the post-earnings weakness. The analyst was most encouraged by the high same-store sales and gross margins improvement. Chen reiterates his Outperform rating and raised his price target to $286 from $265 on Ulta Beauty shares.
PGR Progressive
$32.37

0.7 (2.21%)

09/15/16
KBWI
09/15/16
UPGRADE
Target $31
KBWI
Market Perform
Progressive upgraded to Market Perform from Underperform at Keefe Bruyette
Keefe Bruyette analyst Meyer Shields upgraded Progressive to Market Perform and raised its price target to $31 from $29. The analyst believes most of the catalysts that led to increased 2016 loss ratios year-over-year have played out and rising rates and seasonality should benefit the company.
09/07/16
FBCO
09/07/16
NO CHANGE
FBCO
Progressive, U.S. Silica and Zoetis added to US Focus List at Credit Suisse
Credit Suisse added Progressive (PGR), U.S. Silica (SLCA) and Zoetis (ZTS) to the US Focus List and removed Allison Transmission (ALSN) from the US Focus List and Sealed Air (SEE) from the US Focus List and Global Focus List
06/02/16
06/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) downgraded to Neutral from Buy at BofA/Merrill with analysts led by Doug Leggate saying Exxon's strong relative performance discount's long-term oil at around $73/bbl and said shares appear to be fairly valued. 2. Intuitive Surgical (ISRG) downgraded to Neutral from Buy at Goldman with analyst David Roman saying the risk/reward looks balanced at current share levels. Roman lowered his price target for the stock to $674 from $690. 3. DeVry (DV) downgraded to Neutral from Outperform at Credit Suisse with analyst Trace Urdan saying he no longer feels confident in his investment thesis following the resignation of CFO Tim Wiggins. 4. Franklin Resources (BEN) downgraded to Sell from Neutral at UBS with analyst Brennan Hawken arguing the company is the most exposed to the Department of Labor's fiduciary rule of the names he covers given its reliance on the broker sold channel coupled with weak investment performance. He cut his price target for the shares to $28 from $39. 5. Progressive (PGR) downgraded to Sell from Neutral at Citi with analyst James Naklicki saying consensus margin and earnings expectations are too optimistic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/16
MKMP
08/08/16
NO CHANGE
MKMP
Progressive personal auto seems to be "breaking out," says MKM Partners
MKM Partners analyst Harry Fong says that Progressive's personal auto business "appears to be breaking out," as the company reported that the growth in the number of net premium it wrote accelerated to nearly 12% last quarter. The analyst says he's not concerned by the possibility of the company's combined ratio exceeding 96%, as such an increase would be in-line with its longstanding strategy. He keeps a $40 price target and Buy rating on the shares.
BAX Baxter
$47.51

0.53 (1.13%)

06/08/16
LEER
06/08/16
NO CHANGE
Target $30
LEER
Outperform
NxStage Medical competitive overhang removed, says Leerink
Leerink analyst Danielle Antalffy says Baxter (BAX) announced that it is terminating its VIVIA Home Hemodialysis program, which she believes removes a competitive overhang on NxStage Medical's (NXTM) shares and also discredits a "meaningful" driver of the bear thesis that major customers will "break up" with NxStage Medical once a competitor enters the market. The analyst sees NxStage Medical on track to deliver "solid growth," and reiterates an Outperform rating and $30 price target on its shares.
06/24/16
PIPR
06/24/16
NO CHANGE
PIPR
Medical equipment makers' exposure to U.K. 'manageable,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien estimated that the direct exposure to the U.K. of the medical equipment names in the firm's coverage with the largest Euro/Pound exposure is roughly 5%, which he believes is "manageable." The names in the space with the largest Euro/Pound exposure are Dentsply Sirona (XRAY) Cooper (COO), K2M Group (KTWO), Globus Medical (GMED), ResMed (RMD), Zimmer Biomet (ZBH), Edwards Lifesciences (EW) and Baxter (BAX), said O'Brien, who added that manufacturing may help lessen the impact for Zimmer, Edwards, Baxter and Cooper.
10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Baxter initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Baxter International with an Outperform rating and $53-$55 price target range. The analyst sees "significant balance sheet optionality" for the company to further enhance its organic growth via acquisition and/or sizeable share repurchase programs.
09/15/16
LEHM
09/15/16
INITIATION
Target $52
LEHM
Overweight
Baxter reinstated with an Overweight at Barclays
Barclays analyst Matthew Taylor reinstated Baxter International with an Overweight rating and $52 price target. The analyst sees upside to the company's long-term growth and margin targets.
CSX CSX
$30.21

-0.26 (-0.85%)

10/11/16
VERT
10/11/16
INITIATION
VERT
Hold
CSX initiated with a Hold at Vertical Research
09/13/16
09/13/16
UPGRADE
Target $35

Outperform
Follow-up: CSX upgraded on coal turnaround potential at Wolfe Research
As previously reported, Wolfe Research upgraded CSX to Outperform from Peer Perform with a $35 price target. The firm said coal headwinds are moderating and near-term coal upside given higher nat-gas prices, falling coal inventories, and expectations for a cold winter. The bank said CSX has the most turnaround potential and most leverage to improving margins, and is focused on cost reductions.
09/13/16
WOLF
09/13/16
UPGRADE
WOLF
Outperform
CSX upgraded to Outperform from Peer Perform at Wolfe Research
09/13/16
SBSH
09/13/16
NO CHANGE
Target $170
SBSH
Buy
Rails remain attractive into year-end, says Citi
Citi analyst Christian Wetherbee says he continues to view railroads as the most attractive sector within Transportation into year-end and early 2017. Rail volumes could flatten and begin to turn modestly positive by the end of 2016, which would likely extend investor rotation into the space, Wetherbee tells investors in a research note. He believes valuations in the rails sector remain attractive and that 2017 estimates are achievable. Wetherbee raised his price target for Canadian Pacific (CP) to $170 from $154, for Canadian National (CNI) to $66 from $61, for CSX (CSX) to $32 from $29, for Kansas City Southern (KSU) to $110 from $109, for Norfolk Southern (NSC) to $97 from $87 and for Union Pacific (UNP) to $106 from $100. He has Buy ratings on Canadian Pacific, CSX, Kansas City Southern and Union Pacific.
ALXN Alexion
$118.75

-3.02 (-2.48%)

09/23/16
JEFF
09/23/16
NO CHANGE
Target $120
JEFF
Hold
Alexion price target lowered to $120 from $140 at Jefferies
Jefferies analyst Eun Yang lowered her price target for Alexion Pharmaceuticals to $120 after conducting a survey of 35 U.S. hematologists/nephrologists. The survey results support a cautious outlook on Soliris sales in 2021 and beyond due to potential competition, Yang tells investors in a research note. Specifically, 60% of those surveyed will shift away from Soliris to biosimilars if they are available due to cost, Yang tells investors in a research note. The analyst keeps a Hold rating on Alexion.
10/04/16
BMUR
10/04/16
INITIATION
Target $221
BMUR
Buy
Alexion assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Alexion Pharmaceuticals with a Buy rating and $221 price target.
09/23/16
WEDB
09/23/16
INITIATION
Target $132
WEDB
Neutral
Alexion initiated with a Neutral at Wedbush
Wedbush analyst Heather Behanna initiated Alexion with a Neutral and a $132 price target.
09/26/16
LEER
09/26/16
NO CHANGE
Target $211
LEER
Outperform
Alexion to dominate terminal complement inhibitor market, says Leerink
Leerink analyst Geoffrey Porges expects Alexion's flagship complement inhibition franchise to remain the dominant, if not only, terminal complement inhibitor on the market. The analyst notes that his research finds that the number of manufacturers with competing programs in early stage development face "significant" technical and market-related challenges to match or surpass Soliris. Porges continues to view Alexion's complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases. He reiterates an Outperform rating on the stock and raised his price target on the shares to $211 from $210.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.